Literature DB >> 26809008

Potential Immunomodulatory Effects of Statins in Inflammatory Bowel Disease.

Justin Côté-Daigneault1, Saurabh Mehandru, Ryan Ungaro, Ashish Atreja, Jean-Frédéric Colombel.   

Abstract

Statins are among the most widely prescribed medications in the world. In addition to lowering cholesterol, statins have been shown to have immunomodulatory effects in multiple studies. For example, statins modulate the interaction between T cells and antigen-presenting cells, resulting in decreased T-cell activation and reduced levels of inflammatory cytokines. Statins have also been demonstrated to inhibit the migration of leukocytes across vascular endothelium into tissues. Although most research on the immune effects of statins has been conducted in the context of cardiovascular, rheumatological, or metabolic disease, various studies have shown that statins may have a significant impact on intestinal immunity and mucosal inflammation. Clinical research has suggested that statins may have benefit in inflammatory bowel disease. In this article, we review the effect of statins on the immune system and gastrointestinal tract, highlighting the potential for novel therapeutic applications in inflammatory bowel disease.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26809008     DOI: 10.1097/MIB.0000000000000640

Source DB:  PubMed          Journal:  Inflamm Bowel Dis        ISSN: 1078-0998            Impact factor:   5.325


  14 in total

1.  Response to Cote-Daigneaut et al.

Authors:  Ryan Ungaro; Helena L Chang; Jean-Frederic Colombel
Journal:  Am J Gastroenterol       Date:  2016-12       Impact factor: 10.864

Review 2.  Treating the host response to emerging virus diseases: lessons learned from sepsis, pneumonia, influenza and Ebola.

Authors:  David S Fedson
Journal:  Ann Transl Med       Date:  2016-11

Review 3.  Current and Emerging Uses of Statins in Clinical Therapeutics: A Review.

Authors:  Jonathan T Davies; Spencer F Delfino; Chad E Feinberg; Meghan F Johnson; Veronica L Nappi; Joshua T Olinger; Anthony P Schwab; Hollie I Swanson
Journal:  Lipid Insights       Date:  2016-11-14

4.  A High-Fat Diet Exacerbates the Course of Experimental Trypanosoma cruzi Infection That Can Be Mitigated by Treatment with Simvastatin.

Authors:  Débora Maria Soares de Souza; Guilherme de Paula Costa; Ana Luísa Junqueira Leite; Daniela Silva de Oliveira; Kelerson Mauro de Castro Pinto; Sílvia Elvira Barros Farias; Natália Figueiroa Simões; Nívia Carolina Nogueira de Paiva; Paula Melo de Abreu Vieira; Camilo Adalton Mariano da Silva; Vivian Paulino Figueiredo; Ana Paula de Jesus Menezes; Andre Talvani
Journal:  Biomed Res Int       Date:  2020-06-06       Impact factor: 3.411

Review 5.  Immunomodulatory Effects of Drugs for Effective Cancer Immunotherapy.

Authors:  Maiko Matsushita; Mai Kawaguchi
Journal:  J Oncol       Date:  2018-10-25       Impact factor: 4.375

6.  Simvastatin Evokes An Unpredicted Antagonism For Tamoxifen In MCF-7 Breast Cancer Cells.

Authors:  Amel B Ibrahim; Hala F Zaki; Walaa Wadie; Mervat M Omran; Samia A Shouman
Journal:  Cancer Manag Res       Date:  2019-11-28       Impact factor: 3.989

7.  Acute Statin Treatment Improves Antibody Accumulation in EGFR- and PSMA-Expressing Tumors.

Authors:  Patrícia M R Pereira; Komal Mandleywala; Ashwin Ragupathi; Jason S Lewis
Journal:  Clin Cancer Res       Date:  2020-09-30       Impact factor: 12.531

Review 8.  Cholesterol Metabolism as a Potential Therapeutic Target and a Prognostic Biomarker for Cancer Immunotherapy.

Authors:  Huixian Zhang; Wencheng Zhao; Xingya Li; Yayi He
Journal:  Onco Targets Ther       Date:  2021-06-21       Impact factor: 4.147

9.  Evaluation of tamoxifen and simvastatin as the combination therapy for the treatment of hormonal dependent breast cancer cells.

Authors:  Amel B Ibrahim; Hala F Zaki; Walaa W Ibrahim; Mervat M Omran; Samia A Shouman
Journal:  Toxicol Rep       Date:  2019-10-18

10.  Lipid Profiles in Patients With Ulcerative Colitis Receiving Tofacitinib-Implications for Cardiovascular Risk and Patient Management.

Authors:  Bruce E Sands; Jean-Frédéric Colombel; Christina Ha; Michel Farnier; Alessandro Armuzzi; Daniel Quirk; Gary S Friedman; Kenneth Kwok; Leonardo Salese; Chinyu Su; Pam R Taub
Journal:  Inflamm Bowel Dis       Date:  2021-05-17       Impact factor: 5.325

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.